L-DOPA and Behavior
Title | L-DOPA and Behavior PDF eBook |
Author | Sidney Malitz |
Publisher | |
Pages | 152 |
Release | 1972 |
Genre | Psychology |
ISBN |
Making the Connection Between Brain and Behavior
Title | Making the Connection Between Brain and Behavior PDF eBook |
Author | Joseph H. Friedman, MD |
Publisher | Demos Medical Publishing |
Pages | 261 |
Release | 2013-07-23 |
Genre | Health & Fitness |
ISBN | 1617051756 |
Fully Revised and Updated The only complete and up-to-date book addressing the most common behavioral symptoms of Parkinsonís Disease (PD), including depression, anxiety, hallucinations, disrupted sleep, and compulsive behavior. When people think about PD they usually picture tremor, shuffling, and other physical changes. But as many as 90% of all Parkinsonís patients also live with behavioral symptoms that few families are prepared to handle. In this fully revised and updated edition of Making the Connection Between Brain and Behavior, Dr. Joseph H. Friedman, a leading expert in PD, explains the most common behavioral issues in down-to-earth, straightforward language, offers the most current research on available therapies and medications, and provides guidance on ways to communicate with your healthcare team for effective treatment. Now, fully updated and revised throughout and including three new chapters and two new appendices, Making the Connection Between Brain and Behavior includes even more information on a variety of treatment options, including Electroconvulsive Therapy (ECT). It is an essential resource for every person with PD and his or her family.
L-Dopa and Parkinsonism
Title | L-Dopa and Parkinsonism PDF eBook |
Author | Manuel Riklan |
Publisher | Charles C. Thomas Publisher |
Pages | 424 |
Release | 1973 |
Genre | Medical |
ISBN |
Awakenings
Title | Awakenings PDF eBook |
Author | Oliver Sacks |
Publisher | Vintage |
Pages | 506 |
Release | 2013-05-29 |
Genre | Psychology |
ISBN | 0307834093 |
The classic account of survivors of the sleeping-sickness during the great epidemic just after World War I—and their return to the world after decades of “sleep.” • “One of the most beautifully composed and moving works of our time" (The Washington Post) from the distinguished neurologist and the national bestselling author of The Man Who Mistook His Wife for a Hat. Awakenings—which inspired the major motion picture starring Robert DeNiro and Robin Williams—is the remarkable story of a group of patients who contracted sleeping-sickness during the great epidemic just after World War I. Frozen for decades in a trance-like state, these men and women were given up as hopeless until 1969, when Dr. Oliver Sacks gave them the then-new drug L-DOPA, which had an astonishing, explosive, "awakening" effect. Dr. Sacks recounts the moving case histories of his patients, their lives, and the extraordinary transformations which went with their reintroduction to a changed world.
L-DOPA-induced Serotonin Dysfunction and Associated Behavioral Indices in a Bilateral Rat Model of Parkinson's Disease
Title | L-DOPA-induced Serotonin Dysfunction and Associated Behavioral Indices in a Bilateral Rat Model of Parkinson's Disease PDF eBook |
Author | Karen Louise Eskow-Jaunarajs |
Publisher | |
Pages | 216 |
Release | 2011 |
Genre | Dopa |
ISBN | 9781267162892 |
Levodopa pharmacokinetics -from stomach to brain
Title | Levodopa pharmacokinetics -from stomach to brain PDF eBook |
Author | Maria Nord |
Publisher | Linköping University Electronic Press |
Pages | 81 |
Release | 2019-01-07 |
Genre | |
ISBN | 9176855570 |
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders and it is caused by a loss of dopamine (DA) producing neurons in the basal ganglia in the brain. The PD patient suffers from motor symptoms such as tremor, bradykinesia and rigidity and treatment with levodopa (LD), the precursor of DA, has positive effects on these symptoms. Several factors affect the availability of orally given LD. Gastric emptying (GE) is one factor and it has been shown to be delayed in PD patients resulting in impaired levodopa uptake. Different enzymes metabolize LD on its way from the gut to the brain resulting in less LD available in the brain and more side effects from the metabolites. By adding dopa decarboxylase inhibitors (carbidopa or benserazide) or COMT-inhibitors (e.g. entacapone) the bioavailability of LD increases significantly and more LD can pass the blood-brain-barrier and be converted to DA in the brain. It has been considered of importance to avoid high levodopa peaks in the brain because this seems to induce changes in postsynaptic dopaminergic neurons causing disabling motor complications in PD patients. More continuously given LD, e.g. duodenal or intravenous (IV) infusions, has been shown to improve these motor complications. Deep brain stimulation of the subthalamic nucleus (STN DBS) has also been proven to improve motor complications and to make it possible to reduce the LD dosage in PD patients. In this doctoral thesis the main purpose is to study the pharmacokinetics of LD in patients with PD and motor complications; in blood and subcutaneous tissue and study the effect of GE and PD stage on LD uptake and the effect of continuously given LD (CDS) on LD uptake and GE; in blood and cerebrospinal fluid (CSF) when adding the peripheral enzyme inhibitors entacapone and carbidopa to LD infusion IV; in brain during STN DBSand during oral or IV LD treatment. To conclude, LD uptake is more favorable in PD patients with less severe disease and GE is delayed in PD patients. No obvious relation between LD uptake and GE or between GE and PD stage is seen and CDS decreases the LD levels. Entacapone increases the maximal concentration of LD in blood and CSF. This is more evident with additional carbidopa and important to consider in avoiding high LD peaks in brain during PD treatment. LD in brain increases during both oral and IV LD treatment and the DA levels follows LD well indicating that PD patients still have capacity to metabolize LD to DA despite probable pronounced nigral degeneration. STN DBS seems to increase putaminal DA levels and together with IV LD treatment also increases LD in brain possibly explaining why it is possible to decrease LD medication after STN DBS surgery. Parkinsons sjukdom (PS) är en av de vanligaste s.k. neurodegenerativasjukdomarna och orsakas av förlust av dopamin(DA)producerande nervceller i hjärnan. Detta orsakar motoriska symptom såsom skakningar, stelhet och förlångsammade rörelser. Levodopa (LD) är ett ämne, som kan omvandlas till DA i hjärnan och ge symptomlindring och det är oftast förstahandsval vid behandling av patienter med PS. Flera faktorer påverkar tillgängligheten av LD, bl.a. den hastighet som magsäcken tömmer sig med och denna verkar förlångsammad hos personer med PS vilket ger sämre tillgänglighet av LD i blodet och därmed i hjärnan. LD bryts även ner i hög grad av olika enzym ute i kroppen vilket leder till mindre mängd LD som hamnar i hjärnan och till fler nedbrytningsprodukter som orsakar biverkningar. Tillägg av enzymhämmare leder till ökad mängd LD som kan nå hjärnan och omvandlas till DA. Det anses viktigt att undvika höga toppar av LD i hjärnan då dessa verkar bidra till utvecklandet av besvärliga motoriska komplikationer hos patienter med PS. Om LD ges mer kontinuerligt, exempelvis som en kontinuerlig infusion in i tarmen eller i blodet, så minskar dessa motoriska komplikationer. Inopererande av stimulatorer i vissa delar av hjärnan (DBS) har också visat sig minska dessa motoriska komplikationer och även resultera i att man kan minska LD-dosen. Huvudsyftet med den här avhandlingen är att studera LD hos patienter med PS; i blod och fettvävnad då LD ges i tablettform och se om det finns något samband med LD-upptag och hastigheten på magsäckstömningen (MT) och om kontinuerligt given LD påverkar LD-upptaget eller MT; i blod och i ryggmärgsvätska då enzymhämmarna entakapon och karbidopa tillsätts LD; i hjärna vid behandling med DBS och då LD ges både som tablett och som infusion i blodet. Sammanfattningsvis kan vi se att LD-upptaget är mer gynnsamt hos patienter med PS i tidigare skede av sjukdomens komplikationsfas. MT är förlångsammad hos patienter med PS och det är inget tydligt samband mellan LD-upptag och MT eller mellan MT och sjukdomsgrad. Kontinuerligt given LD minskar LDnivåerna. Enzymhämmaren entakapon ökar den maximala koncentrationen av LD i blod och ryggmärgsvätska och effekten är mer tydlig vid tillägg av karbidopa vilket är viktigt att ta i beaktande vid behandling av PS för att undvika höga toppar av LD i hjärnan. LD ökar i hjärnan då man behandlar med LD i tablettform och som infusion i blodet och DA-nivåerna i hjärnan följer LD väl vilket visar på att patienter med PS fortfarande kan omvandla LD till DA trots trolig uttalad brist av de DA-producerande nervcellerna i hjärnan. DBS verkar öka DA i vissa områden i hjärnan och tillsammans med LD-infusion i blodet verkar det även öka LD i hjärnan och det kan förklara varför man kan sänka LDdosen efter DBS-operation.
Methods of Behavior Analysis in Neuroscience
Title | Methods of Behavior Analysis in Neuroscience PDF eBook |
Author | Jerry J. Buccafusco |
Publisher | CRC Press |
Pages | 341 |
Release | 2000-08-29 |
Genre | Medical |
ISBN | 1420041819 |
Using the most well-studied behavioral analyses of animal subjects to promote a better understanding of the effects of disease and the effects of new therapeutic treatments on human cognition, Methods of Behavior Analysis in Neuroscience provides a reference manual for molecular and cellular research scientists in both academia and the pharmaceutic